BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 23, 2017
View Archived Issues
NIAID begins phase I study of mosquito-borne disease vaccine candidate
Read More
FDA issues complete response letter for Amphastar's intranasal naloxone
Read More
Affigen closes series A financing to support development of cancer immunotherapies
Read More
Truxima becomes the first biosimilar MAb in oncology to be granted E.U. marketing authorization
Read More
BIIB-076 enters phase I study for Alzheimer's disease
Read More
RON kinase, a potential new therapeutic target for cancer-induced bone destruction and osteoporosis
Read More
Aeolus Pharmaceuticals starts phase I study of new formulation of AEOL-10150
Read More
FDA approves Revlimid as maintenance therapy in multiple myeloma after autologous HSCT
Read More
Phase IIa data for GSK-2330672 in patients with primary biliary cholangitis with pruritus
Read More
Prometic Life Sciences reports results from phase II study of PBI-4050 in IPF
Read More
UB-421 monotherapy shows promise for HAART substitution
Read More
ImmusanT completes phase Ib study of Nexvax2
Read More
Kalytera Therapeutics reports phase IIa results for cannabidiol in GvHD
Read More
IMDC recommends discontinuation of ADAPT trial of rocapuldencel-T
Read More
Auris Medical extends collaboration with King's College London
Read More
Revive Therapeutics and InMed in term sheet agreement for cannabinoid therapies for kidney diseases
Read More
Phytecs and Yissum Research Development establish partnership
Read More
University of South Australia patents CDK4/cyclin D1 and/or CDK6/cyclin D3 inhibitors
Read More
FDA grants priority review to Zykadia sNDA for first-line treatment of ALK-positive NSCLC
Read More
NEOMED Institute discovers new bromodomain-containing protein 4 inhibitors
Read More
Achaogen announces milestone in development of plazomicin TDM assay
Read More
Sanofi launches Mozobil in Japan
Read More
NIH leads phase I study of DS-Cav1 vaccine for RSV
Read More